gastric cancer
Conditions
Interventions
test group:chemotherapy by the outcome of chemosensitivity assay
control group:chemotherapy (EOF, DC, XELOX, S-1)
Sponsors
Nantong Tumor Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A histologically proven diagnosis of gastric adenocarcinoma; radical resection of the tumor not more than 8 weeks before the date of random assignment with no evidence of residual disease as determined by staging exams; gastric cancer of stages IB, II, IIIA B, or IV (T4N2M0) according to the American Joint Committee on Cancer - Cancer Staging 2010; Eastern Cooperative Oncology Group performance status (ECOGPS) less than 2; no previous malignancies other than superficial skin cancer or in situ cervical carcinoma; no previous treatments such as neoadjuvant chemotherapy or radiotherapy;and no evidence of abnormal hepatic, renal, or cardiac function. Written informed consent and approval by the local ethics committee was obtained for all patients in the study before random assignment. Surgical procedures were not standardized among participating centers. In the protocol, the minimum surgical recommendations included total or subtotal gastrectomy with negative resection margins with at least D 1 lymphadenectomy dissection.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women of childbearing potential without proper contraceptive methods; 2. Have other malignancies, Central nervous system disease or metastasis, other serious illness or medical condition (infectious disease any pre-existing heart disease, including congestive heart failure, stable and unstable angina etc); 3. patients who cant not understand the object of the study and do not obey orders of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival;Adverse Reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year overall survival;5-year overall survival; | — |
Countries
China
Contacts
Public ContactYang Lei
Outcome results
None listed